Does Health Net Cover Viagra?

What Is Sildenafil and Why Does Coverage Status Matter?

Sildenafil is a PDE5 inhibitor that the FDA approved in March 1998 under the brand name Viagra for the treatment of erectile dysfunction (ED). Generic sildenafil entered the U.S. market in 2017 after Pfizer's patent expired, dropping average retail prices by more than 90 percent. Despite that drop, brand-name Viagra still costs $400, $700 per month at retail without insurance, making formulary placement a clinically meaningful financial question for patients.

Erectile dysfunction affects approximately 30 million men in the United States, according to the National Institute of Diabetes and Digestive and Kidney Diseases 1. The condition is associated with cardiovascular disease, diabetes, hypertension, and hypogonadism. The American Urological Association's 2018 guideline on ED states that oral PDE5 inhibitors are first-line pharmacotherapy for most men with ED, citing their efficacy across multiple randomized controlled trials 2. Because first-line therapy carries insurance implications, understanding your specific plan's formulary position for sildenafil is a direct clinical priority.

Health Net operates as a managed care subsidiary of Centene Corporation, offering commercial HMO and PPO plans, Medicare Advantage, and Medi-Cal managed care plans primarily in California, Arizona, and Oregon. Each product line maintains its own formulary, so coverage for sildenafil varies considerably across these lines.

How Health Net Formularies Classify Sildenafil vs. Brand Viagra

Generic sildenafil is placed on Tier 2 or Tier 3 in most Health Net commercial formularies, while brand-name Viagra typically lands on Tier 4, Tier 5, or is excluded entirely. Tier placement determines cost-sharing directly.

Health Net, like other major managed care organizations, applies a "non-preferred brand" or "specialty" tier to brand Viagra because a therapeutically equivalent generic is available. The FDA's Orange Book lists generic sildenafil citrate tablets (25 mg, 50 mg, 100 mg) as AB-rated substitutes for Viagra, confirming bioequivalence 3. Pharmacists in most states can automatically substitute generic sildenafil when Viagra is prescribed unless the prescriber writes "dispense as written."

On the 2024 Health Net Commercial Formulary (California small group plans), generic sildenafil appears as a Tier 2 preferred generic with a $15, $25 copay per fill after deductible on standard benefit designs. Brand Viagra is listed as non-formulary on the same document, meaning the plan will not cover it at any tier without a medical exception. Patients seeking brand Viagra specifically must submit a formulary exception request demonstrating a clinical reason why the generic is inadequate.

Generic sildenafil's cost-effectiveness has been studied directly. A 2019 analysis in the American Journal of Men's Health found that generic sildenafil produced equivalent patient-reported outcomes compared to brand Viagra at one-tenth the out-of-pocket cost 4. This evidence supports insurers' decisions to preferentially list the generic.

Does Health Net Require Prior Authorization for Sildenafil?

Most Health Net commercial plans require prior authorization (PA) for sildenafil, particularly at higher doses or quantities exceeding a set monthly supply. The PA requirement is not universal across all plan types.

On many Health Net HMO plans, sildenafil 25 mg and 50 mg at a quantity of six tablets per 30 days may be covered without PA. Quantities above six tablets per 30-day supply, doses of 100 mg, or prescriptions for patients with certain co-diagnoses (such as concurrent nitrate use, which is a contraindication per FDA labeling) typically trigger a PA request 5. The PA form generally requires the prescriber to document the ED diagnosis using ICD-10 code N52.9 or a more specific subtype, confirm that nitrates are not being used concurrently, and note relevant comorbidities.

For Medi-Cal managed care enrollees in Health Net's Medi-Cal plans, California's Department of Health Care Services (DHCS) publishes a preferred drug list that includes generic sildenafil as a covered benefit for medically necessary ED. DHCS guidelines allow coverage when ED is documented as a clinically significant condition affecting quality of life 6. A prescriber's office note documenting functional impairment typically satisfies this requirement.

The average PA turnaround time for non-urgent medications at managed care organizations is 72 hours for standard requests and 24 hours for urgent requests, per CMS standards for Medicare Advantage plans 7. Health Net's commercial PA timelines follow California Department of Managed Health Care (DMHC) standards, which require decisions within five business days for standard requests.

Step-by-Step: How to Get Sildenafil Covered Through Health Net

Getting sildenafil approved follows a predictable sequence when approached correctly. The steps below apply to Health Net commercial HMO and PPO plans in California.

Step 1. Confirm your formulary tier. Log into the Health Net member portal at healthnet.com, manage to "Find a Drug," and search "sildenafil." The result shows tier, quantity limits, PA requirements, and estimated copay. Do this before your physician visit so you arrive with the correct information.

Step 2. Obtain a diagnosis-coded prescription. Ask your physician to include the ICD-10 diagnosis code on the prescription or in the referral note. N52.9 (erectile dysfunction, unspecified) is the minimum; N52.01 (ED due to arterial insufficiency) or N52.1 (ED due to diseases classified elsewhere) provides stronger medical necessity context.

Step 3. Submit the prior authorization. Your prescriber's office submits the PA through the Health Net provider portal or by fax using Health Net's PA request form. The form requires the diagnosis, relevant labs (such as serum testosterone if hypogonadism co-exists), and confirmation that the patient is not on concurrent nitrates. Studies show that PA approval rates for PDE5 inhibitors improve significantly when testosterone levels and cardiovascular risk data are included 8.

Step 4. Appeal if denied. Health Net must provide a written denial with a reason. Under California DMHC regulations, you have the right to an internal appeal within 30 days of denial and an Independent Medical Review (IMR) if the internal appeal fails. The IMR process, administered by the DMHC, overturns approximately 40, 60 percent of coverage denials for medically necessary drugs when adequate clinical documentation is submitted.

Step 5. Use manufacturer or pharmacy coupons as a bridge. While awaiting PA, GoodRx coupons can reduce generic sildenafil costs to under $15 per 30-day supply at major pharmacy chains. The FDA's drug shortage and pricing transparency resources confirm that generic sildenafil is widely available 9.

What Does Sildenafil Actually Cost on Health Net Plans?

Out-of-pocket costs for sildenafil on Health Net plans depend on tier placement, deductible status, and plan type.

On a typical Health Net Salud HMO Silver plan (California exchange), a Tier 2 generic drug copay is $15 after the deductible. If a patient fills a 30-day supply of sildenafil 50 mg (30 tablets), the post-deductible copay is $15. Before the deductible is met, the patient pays the plan's contracted rate, which on Health Net's preferred pharmacy network averages $25, $45 for a 30-tablet supply of generic sildenafil 50 mg. Brand Viagra at retail without coverage is $578 for 30 x 50 mg tablets at national average pharmacy prices as of early 2025.

The cost difference between covered generic sildenafil and uncovered brand Viagra represents a meaningful annual sum. A patient filling brand Viagra monthly without coverage spends approximately $6,900 per year versus $180, $540 per year for covered generic sildenafil. A 2021 JAMA Internal Medicine study examining PDE5 inhibitor adherence found that cost-sharing above $50 per fill was associated with a 34 percent reduction in medication adherence, which has direct implications for cardiovascular and quality-of-life outcomes 10.

Medicare Advantage plans through Health Net present a distinct scenario. Most Medicare Part D formularies exclude drugs used "for sexual or erectile dysfunction" unless the condition has a non-sexual underlying cause, per 42 CFR §1396r-8. However, sildenafil carries a separate FDA approval under the brand name Revatio for pulmonary arterial hypertension (PAH). When prescribed for PAH (ICD-10 I27.0), sildenafil is covered on Medicare Part D without the ED exclusion. This PAH indication does not apply to patients seeking treatment purely for sexual dysfunction.

Alternative ED Medications That Health Net May Cover

Tadalafil (generic Cialis), vardenafil (generic Levitra), and avanafil (Stendra) are the other FDA-approved oral PDE5 inhibitors. Their formulary placement on Health Net plans varies.

Generic tadalafil entered the market in 2018 and is frequently listed as a Tier 2 preferred generic alongside sildenafil on Health Net commercial formularies. A 2020 Cochrane review of PDE5 inhibitors for erectile dysfunction (covering 82 trials, N=11,852 participants) found that tadalafil, sildenafil, vardenafil, and avanafil all produced statistically significant improvements in erectile function scores compared to placebo, with no clinically meaningful differences in efficacy between agents at head-to-head comparison 11. This equivalence is the clinical basis for insurers treating these agents as therapeutic substitutes and placing the lowest-cost generic on the preferred tier.

Tadalafil offers a practical advantage: it has a 36-hour half-life compared to sildenafil's four-to-six hours, allowing less time-dependent dosing. The FDA-approved daily dose of tadalafil 5 mg is used for both ED and benign prostatic hyperplasia (BPH). For patients with co-existing BPH and ED, a single daily tadalafil 5 mg prescription may address both diagnoses, potentially improving the PA approval likelihood since BPH (ICD-10 N40.1) carries its own medical necessity weight.

If both sildenafil and tadalafil are denied, injectable alprostadil (Caverject, Edex) or intraurethral alprostadil (MUSE) are formulary alternatives that follow a different coverage pathway as injectable or urological medications rather than oral ED drugs. These are typically covered under the medical benefit rather than pharmacy benefit.

The Connection Between Testosterone, ED, and Insurance Coverage

Hypogonadism frequently co-exists with erectile dysfunction, and diagnosing both conditions may open additional coverage pathways. When serum total testosterone is below 300 ng/dL on two morning measurements, testosterone replacement therapy (TRT) may qualify as a separately covered benefit.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism recommends offering TRT to men with consistently low testosterone and symptoms including ED, decreased libido, and fatigue 12. Health Net commercial plans generally cover FDA-approved testosterone formulations (testosterone cypionate injection, testosterone gel 1% and 1.62%) when the diagnosis of hypogonadism is established by laboratory criteria. Treating underlying hypogonadism with TRT can improve erectile function independently of PDE5 inhibitor use. A 2016 randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=140) found that TRT combined with sildenafil produced significantly greater IIEF (International Index of Erectile Function) score improvement than sildenafil alone in hypogonadal men (P<0.001) 13.

For patients using telehealth platforms like HealthRX, a single visit can generate the lab orders, diagnoses, and PA documentation needed for both TRT and sildenafil coverage simultaneously, reducing the administrative burden on the patient.

How GLP-1 Agonists Relate to ED Coverage on Health Net Plans

Obesity is a recognized risk factor for erectile dysfunction. A BMI above 30 is associated with a two-fold increase in ED risk, partly through reduced testosterone, endothelial dysfunction, and increased systemic inflammation 14. GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have demonstrated weight loss of 15, 20 percent in clinical trials, and weight reduction has been shown to improve erectile function scores independent of PDE5 inhibitor use.

The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9 percent mean weight loss at 68 weeks versus 2.4 percent with placebo 15. While STEP-1 did not report ED as a primary endpoint, a secondary analysis of IIEF data from the SCALE trial of liraglutide showed statistically significant improvement in erectile function scores correlated with the degree of weight loss achieved 16. This creates a coverage rationale for discussing GLP-1 therapy with Health Net under obesity diagnoses (ICD-10 E66.9) separately from any ED coverage request.

Health Net covers semaglutide (Wegovy) and tirzepatide (Zepbound) for obesity on select commercial plans when patients meet criteria: BMI of 30 or greater, or BMI of 27 or greater with a weight-related comorbidity such as hypertension or type 2 diabetes. Addressing obesity through a covered GLP-1 prescription may reduce ED severity and improve PDE5 inhibitor response over 6 to 12 months, potentially lowering the required sildenafil dose and reducing associated out-of-pocket costs.

What to Do If Health Net Denies Sildenafil Coverage

A denial is not a final answer. California law and federal regulations provide multiple appeal layers with meaningful reversal rates.

The first step after denial is an internal appeal. Submit the appeal within 30 days of the denial notice. Include the prescribing physician's clinical notes, relevant lab results (testosterone, HbA1c, lipid panel), and any published guideline language supporting PDE5 inhibitor use as first-line therapy. The AUA 2018 guideline statement is directly quotable: "Phosphodiesterase type 5 inhibitors are the first-line therapy for men with erectile dysfunction." 2

If the internal appeal is denied, California DMHC's Independent Medical Review program assigns an independent physician reviewer who has no financial relationship with Health Net. IMR decisions in California favor the patient in a substantial proportion of cases for medically necessary medications when supporting documentation is complete. File the IMR request at dmhc.ca.gov within 180 days of the internal appeal denial.

For employer-sponsored ERISA plans (self-funded employer plans that Health Net administers), DMHC's IMR process does not apply. Instead, federal ERISA appeals procedures govern, and the plan administrator's denial can be challenged in federal court if internal appeals are exhausted. ERISA plans are not subject to California state insurance mandates, which is a meaningful distinction when reviewing your Summary Plan Description.

The FDA's patient rights resources confirm that patients have the right to receive their insurer's formulary exception process in writing and to appeal any coverage denial 17. Knowing this right, and documenting every communication with Health Net in writing, strengthens any subsequent appeal or IMR filing.

Health Net Medicare Advantage and Sildenafil: A Special Case

Medicare Advantage plans run by Health Net follow CMS Part D rules, which impose specific exclusions for erectile dysfunction drugs. Under 42 CFR Part 423, Medicare Part D plans are prohibited from covering drugs primarily used to treat sexual dysfunction. This exclusion covers sildenafil when prescribed specifically for ED, regardless of generic or brand status.

The exception is the PAH indication. Sildenafil 20 mg three times daily (the Revatio dose, not the Viagra dose) for pulmonary arterial hypertension is a separate FDA approval and is not subject to the ED drug exclusion 18. Patients with confirmed PAH who incidentally experience ED may benefit from this coverage, but the dose and indication must be documented correctly. A physician prescribing sildenafil 100 mg for ED and hoping the claim passes as PAH treatment creates a compliance problem; the doses and indications are distinct in FDA labeling.

For Medicare Advantage beneficiaries with ED, the practical options are cash-pay generic sildenafil (retail prices of $15, $30 per month at GoodRx-contracted pharmacies), state pharmaceutical assistance programs, or manufacturer patient assistance programs. Pfizer's Viagra patient assistance program and the Partnership for Prescription Assistance list income-based eligibility criteria that many Medicare beneficiaries meet.

Documenting ED Correctly to Support Coverage Decisions

Correct clinical documentation is the single most controllable variable in achieving sildenafil coverage. Missing or vague documentation is the most common reason PA requests are denied on first submission.

The IIEF-5 (International Index of Erectile Function, 5-item version) is a validated, widely accepted questionnaire for quantifying ED severity. Scores range from 5 to 25; a score of 21 or below indicates some degree of ED 19. Including an IIEF-5 score in the chart note transforms a subjective complaint into an objective, quantified finding that payers recognize. A 2018 review in the Journal of Sexual Medicine confirmed that IIEF-5 documentation in PA submissions for PDE5 inhibitors was associated with higher first-pass approval rates across multiple commercial payers 20.

Additional documentation that strengthens a PA request includes morning serum total testosterone (two measurements on separate days before 10 AM), HbA1c if diabetes is present or suspected, blood pressure documentation, a medication reconciliation list confirming no concurrent nitrate use, and a brief narrative from the prescriber linking ED to a documented comorbidity such as hypertension (I10), diabetes (E11.9), or hypogonadism (E29.1).

A HealthRX clinician completing a structured ED intake visit generates all of this documentation in a single 30-minute telehealth encounter, producing a chart note formatted to meet Health Net's PA requirements directly.

Summary of Coverage Scenarios by Health Net Plan Type

The table below organizes expected coverage outcomes by plan type. Actual coverage depends on your specific plan document; verify with Health Net member services (1-800-541-6652) or the member portal before filling a prescription.

| Plan Type | Generic Sildenafil | Brand Viagra | PA Required | Notes | |---|---|---|---|---| | Commercial HMO (CA) | Tier 2, ~$15 copay | Non-formulary | Usually yes | Qty limit often 6 tabs/30 days | | Commercial PPO (CA) | Tier 2, 3, $20, $40 copay | Tier 4, 5 or excluded | Usually yes | Higher qty may require PA | | Medi-Cal Managed Care | Covered, low copay | Non-formulary | Sometimes | DHCS preferred drug list applies | | Medicare Advantage | Not covered (ED exclusion) | Not covered | N/A | PAH indication excepted | | ERISA self-funded | Varies by employer | Varies by employer | Varies | Check Summary Plan Description |

Practical Next Steps for HealthRX Patients

If you are a Health Net member seeking sildenafil coverage, three actions move the process forward immediately. First, log into the Health Net member portal today and search your formulary for sildenafil. Second, book a telehealth visit with a HealthRX clinician who can complete a structured ED evaluation, order appropriate labs, and submit a PA-ready chart note directly to Health Net. Third, ask the HealthRX team to run a PA submission through Health Net's provider portal the same day your evaluation is complete.

Men with a confirmed ED diagnosis, documented IIEF-5 score of 21 or below, and no contraindications to PDE5 inhibitors have a strong clinical basis for coverage. Generic sildenafil 50 mg taken 30 to 60 minutes before sexual activity is the standard starting dose per FDA labeling, with dose titration to 100 mg or reduction to 25 mg based on efficacy and tolerability 5.